{"id":2543,"date":"2018-03-01T12:00:00","date_gmt":"2018-03-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/medikamentoese-initialbehandlung-bei-schweren-unipolaren-depressionen"},"modified":"2022-03-17T14:13:44","modified_gmt":"2022-03-17T13:13:44","slug":"medikamentoese-initialbehandlung-bei-schweren-unipolaren-depressionen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/medikamentoese-initialbehandlung-bei-schweren-unipolaren-depressionen","title":{"rendered":"Medikament\u00f6se Initialbehandlung bei schweren unipolaren Depressionen"},"content":{"rendered":"<p>Zusammenfassung: Die gr\u00f6\u00dfte bisher durchgef\u00fchrte Metaanalyse zur Behandlung mit Antidepressiva kommt zu dem Schluss, dass Antidepressiva bei mittelschweren und schweren Episoden einer unipolaren Depression durchweg wirksamer sind als Plazebo. Die Akzeptanz der Therapie \u2013 gemessen an der Abbruchrate (\u201edropout rate\u201c) \u2013 variiert sehr stark zwischen den einzelnen Wirkstoffen, liegt aber im Mittel im Bereich von [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die gr\u00f6\u00dfte bisher durchgef\u00fchrte Metaanalyse zur Behandlung mit Antidepressiva kommt zu dem Schluss, dass Antidepressiva bei mittelschweren und schweren Episoden einer unipolaren Depression durchweg wirksamer sind als Plazebo. Die Akzeptanz der Therapie \u2013 gemessen an der Abbruchrate (\u201edropout rate\u201c) \u2013 variiert sehr stark zwischen den einzelnen Wirkstoffen, liegt aber im Mittel im Bereich von [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2850,2852,3643,618,255,2849,2118,397,2055,1254,4987,1370,2052,920,391,4989,257,2281,2190,1672,4333,4988,4332,922,1735,381,900,902,375,903,377,2847,756,379,4986,4709],"class_list":["post-2543","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-adhaerenz","tag-adherence","tag-agomelatin","tag-amitriptylin","tag-arzneimittel","tag-arzneimittel-adhaerenz","tag-bupropion","tag-citalopram","tag-clomipramin","tag-depression","tag-desvenlavaxin","tag-duloxetin","tag-escitalopram","tag-fluoxetin","tag-fluvoxamin","tag-levomilnacipran","tag-medikamente","tag-milnacipran","tag-mirtazapin","tag-nefazodon","tag-nicht-adhaerenz","tag-nichtselektive-monoamin-wiederaufnahmehemmer","tag-non-adherence","tag-paroxetin","tag-reboxetin","tag-selektive-serotonin-wiederaufnahme-hemmer","tag-serotonin-noradrenalin-wiederaufnahme-hemmer","tag-serotonin-norepinephrin-wiederaufnahme-hemmer","tag-sertralin","tag-snri","tag-ssri","tag-therapietreue","tag-trazodon","tag-venlafaxin","tag-vilazodon","tag-vortioxetin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2543"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2543\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}